Drug chirality: A consideration of the significance of the stereochemistry of antimicrobial agents

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 1, 1996, Pages 7-32

  Hutt, A J ^a   O'Grady, J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Daiichi Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; LATAMOXEF; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CHIRALITY; DIASTEREOISOMER; DRUG STRUCTURE; RACEMIC MIXTURE; REVIEW; STEREOCHEMISTRY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CARBAPENEMS; FLUOROQUINOLONES; HUMANS; MOLECULAR CONFORMATION; PRODRUGS; TERMINOLOGY;

EID: 0029968911     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.1.7     Document Type: Review

References (84)

1. Albers-Sehönberg, G., Arisen, B. H., Hensens, O. D., Hirschfield, JL, Hoogsteen, K., Kaczka, E. A. et al. (1978). Structure and absolute configuration of thienamycin. Journal of the American Chemical Society 100, 6491-9.
2. Ariens, E. J. (1984). Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. European Journal of Clinical Pharmacology 26, 663-8.
3. Ariens, E. J., Wuis, E. W. & Veringa, E. J. (1988). Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochemical Pharmacology 37, 9-18.
4. Atarashi, S., Yokohama, S., Yamazaki, K.-I., Sakano, K.-I., Imamura, M. & Hayakawa, I. (1987). Synthesis and antibacterial activities of optically active ofloxacin and its fluoromethyl derivative. Chemical and Pharmaceutical Bulletin 35, 1896-902.
5. Barza, M. (1985). Imipenem: first of a new class of beta-lactam antibiotics. Annals of Internal Medicine 103, 552-60.
6. Bauernfeind, A., Jungwirth, R., Eberlein, E., Kiesel, N., Adam, F., Isert, D. et al. (1992). RU 29246, the active compound of the cephalosporin prodrug-ester HR916. I. Antibacterial activity in vitro. Journal of Antibiotics 45, 505-20.
7. Birnbaum, J., Kahan, F. M., Kropp, H. & MacDonald, J. S. (1985). Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. American Journal of Medicine 78, Suppl. 6A. 3-21.
8. Blaschke, G., Kraft, H. P., Fickentscher, K. & Köhler, F. (1979). Chromatographische racemattrennung von thalidomid und teratogene wirkung der enantiomere. Arzneimittel Forschung 29, 1640-2.
9. British Pharmacopoeia. (1993). Vol. 1, pp. 45-46, 120-121, 132-133. HMSO, London.
10. Caldwell, J., Winter, S. M. & Hutt, A. J. (1988). The pharmacological and texicological significance of the stereochemistry of drug disposition. Xenobiotica 18, Suppl. 1, 59-70.
11. Campbell, C. J., Chantrell, L. J. & Eastmond, R. (1987). Purification and partial characterization of rat intestinal cefuroxime axetil esterase. Biochemical Pharmacology 36, 2317-24.
12. Cayen, M. N. (1991). Racemic mixtures and single stereoisomers: industrial concerns and issues in drug development. Chirality 3, 94-8.
13. Chu, D. T. W., Fernandes, P. B., Claiborne, A. K., Shen, L. & Pernet, A. G. (1989). Structure-activity relationships in quinolone antibacterials: replacement of the 3-carboxylic acid group. In Quinolones, Proceedings of an International Telesymposium (Fernandes, P. B., Ed.), pp. 37-45. J. R. Prous Science. Barcelona.
14. Chu, D. T. W., Nordeen, C. W., Hardy, D- J., Swanson, R. N., Giardina, W. J., Pernet, A. G. et al. (1991). Synthesis, antibacterial activities and pharmacological properties of enantiomers of temafloxacin hydrochloride. Journal of Medicinal Chemistry 34, 168-74.
15. Clissold, S. P., Todd, P. A. & Campoli-Richards, D. M. (1987). Imipenem cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 33, 183-241.
16. Controulis, J., Rebstock, M. C. & Crooks, H. M. (1949). Chloramphenicol (Chloromycetin). V. Synthesis. Journal of the American Chemical Society 71, 2463-8.
17. Davis, R. & Bryson, H. M. (1994). Levofloxacin, a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700.
18. De Camp, W. H. (1989). The FDA perspective on the development of stereoisomers. Chirality 1, 2-6.
19. Defossa, E., Dürckheimer, W., Fischer, G., Jendralla, H., Kiesel, N. & Wollmann, T. (1992). Cefdaloxime Pentexil Tosilate (HR 916 K): a diastereomerically pure novel oral cephalosporinester: synthesis and antibacterial activity in vivo. In Program and Abstracts of the Twenty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 187, p. 142. American Society for Microbiology, Washington, DC.
20. Doyle, F. P., Fosker, G. R., Naylor, J. H. C. & Smith, H. (1962). Derivatives of 6-aminopenicillanic acid. Part I α-aminobenzylpenicillin and some related compounds. Journal of the Chemical Society 1440-4.
21. Ernest, I., Gosteli, J. & Woodward, R. B. (1979). The penems, a new class of β-lactam antibiotics, 3. Synthesis of optically active 2-methyl-(5A)-penem-3-carboxylic acid. Journal of the American Chemical Society 101, 6301-5.
22. Fabre, H., Ibork, H. & Lerner, D. A. (1994). Photoisomerization kinetics of cefuroxime axetil and related compounds. Journal of Pharmaceutical Sciences 83, 553-8.
23. Fabro, S., Smith, R. L. & Williams, R. T. (1967). Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215, 269.
24. Finn, A., Straughn, A., Meyer, M. & Chubb, J. (1987). Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharmaceutics and Drug Disposition 8, 519-26.
25. Gerster, J. F., Rohlfing, S. R., Pecore, S. E., Winandy, R. M., Stern, R. M., Landmesser, J. E. et al. (1987). Synthesis, absolute configuration and antibacterial activity of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid. Journal of Medicinal Chemistry 30, 839-43.
26. Gerster, J. F., Rohlfing, S. R., Rustad, N. J., Reiter, M. J., Pecore, S. E., Winandy, R. M. et al. (1989). The synthesis and pharmacological profile of the stereoisomers of a tricyclic quinolone antibacterial. In Quinolones, Proceedings of an International Telesymposium (Fernandes, P. B., Ed.), pp. 85-98. J. R. Prous Science, Barcelona.
27. Georgopapadakou, N. H., Dix, B. A., Angehrn, P., Wick, A. & Olson, G. L. (1987). Monocyclic and tricyclic analogues of quinolones: mechanism of action. Antimicrobial Agents and Chemotherapy 31, 614-6.
28. Graham, D. W., Ashton, W. T., Barash, L., Brown, J. E., Brown, R. D., Canning, L. F. et al. (1987). Inhibition of the mammalian β-lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted-propenoic acids. Journal of Medicinal Chemistry 30, 1074-90.
29. Harding, S. M., Williams, P. E. O. & Ayrton, J. (1984). Pharmacology of cefuroxime as the I-acetoxyethyl ester in volunteers. Antimicrobial Agents and Chemotherapy 25, 78-82.
30. Hawkes, N. (1993). Lateral thinking. Times Magazine, 5th June, pp. 30-31.
31. Hayakawa, I., Atarashi, S., Kimura, Y., Kawakami, K., Saito, T., Yafune, T. et al. (1991). Design and structure-activity relationship of new N-cis-2-fluorocyclopropyl quinolones. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 1504. American Society for Microbiology, Washington, DC.
32. Hayakawa, I., Atarashi, S., Yokohama, S., Imamura, M., Sakano, K.-L & Furukawa, M. (1986). Synthesis and antibacterial activities of optically active ofloxacin. Antimicrobial Agents and Chemotherapy 29, 163-4.
33. Hendel, J. & Brodthagen, H. (1984). Enterohepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. European Journal of Clinical Pharmacology 26, 103-7.
34. Hoover, J. R. E. & Dunn, G. L. (1979). The β-lactam antibiotics. In Burgee's Medicinal Chemistry, 4th edn, part II (Wolff, M. E., Ed.), pp. 83-172. John Wiley, New York.
35. Hoshino, K., Hayakawa, I., Sato, K., Sato, M., Kitamura, A. & Osada, Y. (1991a). Inhibitory effects of DU-6859, a new fluorinated quinolone on type II topoisomerases. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 1506. American Society for Microbiology, Washington, DC.
36. Hoshino, K., Sato, K., Akahane, K., Yoshida, A., Hayakawa, I., Sato, M. et al. (1991b). Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrobial Agents and Chemotherapy 35, 309-12.
37. Hutt, A. J. (1990). Enantiospecific analytical methodology: applications in drug metabolism and pharmacokinetics. In Progress in Drug Metabolism, Vol. 12 (Gibson, G. G., Ed.), pp. 257-361. Taylor and Francis, London.
38. Imamura, M., Shibamura, S., Hayakawa, I. & Osada, Y. (1987). Inhibition of DNA gyrase by optically active ofloxacin. Antimicrobial Agents and Chemotherapy 31, 325-7
39. Isert, D., Fischer, G., Kiesel, N., Limbert, M., Markus, A., Riess, G. et al. (1992). Cefdaloxime Pentexil Tosilate (HR 916 K): a diastereomerically pure novel oral cephalosporinester with outstanding absorption characteristics. In Program and Abstracts of the Twenty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 188, p. 142. American Society for Microbiology, Washington, DC.
40. Kahan, F. M., Kropp, H., Sundelof, J. G. & Birnbaum, J. (1983). Thienamycin: development of iminpenem-cilastatin. Journal of Antimicrobial Chemotherapy 12, Suppl. D, 1-35.
41. Kim, H. S. & Campbell, B. J. (1982). β-Lactamase activity of renal dipeptidase against N-formimidoyl-thienamycin. Biochemical and Biophysical Research Communications 108, 1638-42.
42. Kitzes-Cohen, R. (1989). CNS pharmacokinetics of quinolones. Quinolones in CNS infections. In Quinolones, Proceedings of an International Telesymposium (Fernandes, P. B., Ed.). pp. 313-26. J. R. Prous Science, Barcelona.
43. Kropp, H., Gerckens, L., Sundelof, J. G. & Kahan, F. M. (1985). Antibacterial activity of imipenem: the first thienamycin antibiotic. Reviews of Infectious Diseases 7, Suppl. 3, S389-S410.
44. Kropp, H., Sundelof, J. G., Hajdu, R. & Kahan, F. M. (1982). Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrobial Agents and Chemotherapy 22, 62-70.
45. Lehmann, P. A. F., DeMiranda, J. F. R. & Ariens, E. J. (1976). Stereoselectivity and affinity in molecular pharmacology. In Progress in Drug Research, Vol. 20 (Junker, E, Ed.), pp. 101-42. Birkhäuser Verlag, Basle.
46. Lüthy, R., Blaser, J., Bonetti, A., Simmen, H., Wise, R. & Siegenthaler, W. (1981). Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam and ceftazidime. Antimicrobial Agents and Chemotherapy 20, 567-75.
47. Markus, A., Kiesel, N., Wollmann, T., Isert, D., Limbert, M., Schrinner, E. et al. (1992). RU 29 296, the active compound of the cephalosporin prodrug-ester HR 916. II Stability to β-lactamases and affinity for penicillin-binding proteins. Journal of Antibiotics 45, 521-6.
48. Mason, S. (1984). The left hand of nature. New Scientist 101, 10-4.
49. Matteson, D. (1991). Through the chemical looking glass. New Scientist 132, 35-9.
50. McCombie, S. W. & Ganguly, A. K. (1988). Synthesis and in vitro activity of the penem antibiotics. Medicinal Research Reviews 8, 393-440.
51. Mendes, P., Meyer, B. H., Müller, F. O., Scholl, T., Luus, H. & de la Rey, N. (1992). Pharmacokinetics of cefdaloxime pentexil tosilate (HR 916 K) after a single oral dose in healthy volunteers. In Program and Abstracts of the Twenty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 189, p. 142. American Society for Microbiology, Washington, DC.
52. Millership, J. S. & Fitzpatrick, A. (1993). Commonly used chiral drugs: a survey. Chirality 5, 573-6.
53. Mitscher, L. A., Sharma, P. N., Chu, D. T. W., Shen, L. L. & Pernet, A. G. (1987). Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3- de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). Journal of Medicinal Chemistry 30, 2283-6.
54. Mitscher, L. A., Sharma, P. N. & Zavod, R. M. (1989). The influence of optical isomerism on the biological properties of quinolone antimicrobial agents. In Quinolones, Proceedings of an International Telesymposium (Fernandes, P. B., Ed.), pp. 73-83. J. R. Prous Science, Barcelona.
55. Moellering, R. C., Eliopoulos, G. M. & Sentochnik, D. E. (1989). The carbapenems: new broad spectrum β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 24, Suppl. A., 1-7.
56. Moran, N. (1993). Drug firms sort their lefts from their rights. Independent on Sunday, 7th November.
57. Mosher, G. L., McBee, J. & Shaw, D. B. (1992). Esterase activity toward the diastereomers of cefuroxime axetil in the rat and dog. Pharmaceutical Research 9, 687-9.
58. Nation, R. L. (1994) Chirality in new drug development. Clinical Pharmacokinetic considerations. Clinical Pharmacokinetics 27, 249-55.
59. Naylor, J. H. C. (1973). Advances in penicillin research. In Advances in Drug Research, Vol. 7 (Harper, N. J. & Simmonds, A. B., Eds), pp. 1-105. Academic Press, London.
60. Okazaki, O., Kojima, C , Hakusui, H. & Nakashima, M. (1991a). Enantioselective disposition of ofloxacin in humans. Antimicrobial Agents and Chemotherapy 35, 2106-9.
61. Okazaki, O., Kurata, T., Hakusui, H. & Tachizawa, H. (1991b). Stereoselective glucuronidation of ofloxacin in rat liver microsomes. Drug Metabolism and Disposition 19, 376-80.
62. Okazaki, O., Kurata, T., Hakusui, H. & Tachizawa, H. (1992). Species-related Stereoselective disposition of ofloxacin in the rat, dog and monkey. Xenobiotica 22, 439-50.
63. Okazaki, O., Kurata, T. & Tachizawa, H. (1989). Stereoselective metabolic disposition of enantiomers of ofloxacin in rats. Xenobiotica 19, 419-29.
64. Parsons, W. H., Hajdu, R., Schoen, W. R., Combs, P. L., Sundelof, J. & Patchett, A. A. (1991). A new class of potent, slowly reversible dehydropeptidase inhibitors. Biochemistry International 23, 1107-15.
65. Pfaendler, H. R., Gosteli, J. & Woodward, R. B. (1979). The penems, a new class of β-lactam antibiotics. 4. Syntheses of racemic and enantiomeric penem carboxylic acids. Journal of the American Chemical Society 101, 6306-10.
66. Ratcliffe, R. W., Wildonger, K. J., DiMichele, L., Douglas, A. W., Hajdu, R., Goegelman, R. T. et al. (1989). Studies on the structures of imipenem, dehydropeptidase I hydrolyzed imipenem and related analogues. Journal of Organic Chemistry 54, 653-60.
67. Rauws, A. G. & Groen, K. (1994). Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. Chirality 6, 72-5.
68. Rebstock, M. C., Crooks, H. M., Controulis, J. & Bartz, Q. R. (1949). Chloramphenicol (Chloromycetin) IV Chemical studies. Journal of the American Chemical Society 71, 2458-62.
69. Rosen, T., Chu, D. T. W., Lico, I. M., Fernandes, P. B., Shen, L., Borodkin, S. and Pernet, A. G. (1988). Asymmetric synthesis and properties of the enantiomers of the antibacterial agent 7-(3-aminopyrrolidin-1-yl)-1 -(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride. Journal of Medicinal Chemistry 31, 1586-90.
70. Sato, K., Hoshino, K. & Mitsuhashi, S. (1992a). Mode of action of new quinolones: the inhibitory activity of DNA gyrase. In Progress in Drug Research, Vol. 38, pp. 121-132. Birkhäuser Verlag, Basle.
71. Sato, K., Hoshino, K., Tanaka, M., Hayakawa, I. & Osada, Y. (1992b). Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrobial Agents and Chemotherapy 36, 1491-8.
72. Sato, K., Hoshino, K., Tanaka, M., Hayakawa, I., Osada, Y., Nishino, T. et al. (1993). Antibacterial activity of new quinolones and their modes of action. In Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy (Andoh, T., Ikeda, H. & Oguro, M., Eds), pp. 167-76. CRC Press, Boca Raton.
73. Shen, L. L. (1993). Quinolone-DNA interaction. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 77-95. American Society for Microbiology, Washington, DC.
74. Shen, L. L. (1994). Molecular mechanisms of DNA Gyrase inhibition by quinolone antibacterials. In DNA Topoisomerases: Biochemistry and Molecular Biology (Liu, L. F., Ed.) Advances in Pharmacology, Vol. 29A, pp. 285-304. Academic Press, London.
75. Shen, L. L., Bures, M. G., Chu, D. T. W. & Plattner, J. J. (1990). Quinolone-DNA interaction: how a small drug molecule acquires high DNA binding affinity and specificity. In Molecular Basis of Specificity in Nucleic Acid-Drug Interactions (Pullman. B. & Jortner, J., Eds), pp. 495-512. Kluwer Academic, Dordrecht.
76. Shen, L. L., Mitscher, L. A., Sharma, P. N., O'Donnell, T. J., Chu, D. W. T., Cooper, C. S. et al. (1989). Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 28, 3886-94.
77. Tamai, I., Ling, H.-Y., Timbul, S. M., Nishikido, J. & Tsuji, A. (1988). Stereospecific absorption and degradation of cephalexin. Journal of Pharmacy and Pharmacology 40, 320-4.
78. Testa, B., Carrupt, P.-A. & Gal, J. (1993). The so-called "interconversion" of stereoisomeric drugs: an attempt at clarification. Chirality 5, 105-11.
79. Tucker, G. T. & Lennard, M. S. (1990). Enantiomer specific pharmacokinetics. Pharmacology and Therapeutics 45, 309-29.
80. Une, T., Fujimoto, T., Sato, K. & Osada, Y. (1988). In vitro activity of DR-3355, an optically active ofloxacin. Antimicrobial Agents and Chemotherapy 32, 1336-40.
81. Williams, K. & Lee, E. (1985). Importance of drug enantiomers in clinical pharmacology. Drugs 30, 333-54.
82. Wise, R., Wills, P. J. & Bedford, K. A. (1981). Epimers of moxalactam: in vitro comparison of activity and stability. Antimicrobial Agents and Chemotherapy 20, 30-2.
83. Yamada, H., Ichihashi, T., Hirano, K. & Kinoshita, H. (1981). Plasma protein binding and urinary excretion of R- and 5-epimers of an arylmalonylamino-1-oxacephem I: in humans. Journal of Pharmaceutical Sciences 70, 112-3.
84. Zak, O., Lang, M., Cozens, R., Konopka, E. A., Mett, H., Schneider, P. et al. (1988). Penems: in vitro and in vivo experiments. Journal of Clinical Pharmacology 28, 128-35.